JP2017514866A - Ｂｒａｆ阻害剤を使用する創傷治癒 - Google Patents

Ｂｒａｆ阻害剤を使用する創傷治癒 Download PDF

Info

Publication number
JP2017514866A
JP2017514866A JP2016566754A JP2016566754A JP2017514866A JP 2017514866 A JP2017514866 A JP 2017514866A JP 2016566754 A JP2016566754 A JP 2016566754A JP 2016566754 A JP2016566754 A JP 2016566754A JP 2017514866 A JP2017514866 A JP 2017514866A
Authority
JP
Japan
Prior art keywords
dressing
group
braf inhibitor
wound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514866A5 (enExample
Inventor
リバス アントニー
リバス アントニー
エスクイン オーディナス ヘレナ
エスクイン オーディナス ヘレナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017514866A publication Critical patent/JP2017514866A/ja
Publication of JP2017514866A5 publication Critical patent/JP2017514866A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016566754A 2014-05-06 2015-05-06 Ｂｒａｆ阻害剤を使用する創傷治癒 Pending JP2017514866A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989398P 2014-05-06 2014-05-06
US61/989,398 2014-05-06
PCT/US2015/029562 WO2015171833A1 (en) 2014-05-06 2015-05-06 Wound healing using braf inhibitors

Publications (2)

Publication Number Publication Date
JP2017514866A true JP2017514866A (ja) 2017-06-08
JP2017514866A5 JP2017514866A5 (enExample) 2018-06-21

Family

ID=54392978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566754A Pending JP2017514866A (ja) 2014-05-06 2015-05-06 Ｂｒａｆ阻害剤を使用する創傷治癒

Country Status (5)

Country Link
US (1) US20170100345A1 (enExample)
EP (1) EP3139927A4 (enExample)
JP (1) JP2017514866A (enExample)
CN (1) CN106535900A (enExample)
WO (1) WO2015171833A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530457A (ja) * 2017-08-08 2020-10-22 メモリアル スローン ケタリング キャンサー センター Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
JP2022519675A (ja) * 2019-02-12 2022-03-24 ルトリス ファーマ エル ティー ディー． 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017154001A1 (en) * 2016-03-10 2017-09-14 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions
JP2019522652A (ja) * 2016-06-21 2019-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｂｒａｆ阻害剤を用いる創傷治癒
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018195392A1 (en) * 2017-04-20 2018-10-25 Thomas Jefferson University Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation
BR112020001935A2 (pt) * 2017-07-29 2020-07-28 Lutris Pharma Ltd novos inibidores de braf e uso destes para o tratamento de reações cutâneas
CN111417730A (zh) * 2017-11-20 2020-07-14 托雷莫治疗股份公司 诊断方法
EP3897630B1 (en) 2018-12-21 2024-01-10 Celgene Corporation Thienopyridine inhibitors of ripk2
DE102019129444A1 (de) * 2019-10-31 2021-05-06 Lts Lohmann Therapie-Systeme Ag Lagtime-Verkürzung/Eisspray

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506908A (ja) * 1996-12-20 2001-05-29 プロサイト コーポレイション 吸収性ヒドロゲル粒子および創傷用ドレッシングにおけるその使用
JP2003192598A (ja) * 2001-12-27 2003-07-09 Mikasa Seiyaku Co Ltd 創傷治療用製剤
JP2008546797A (ja) * 2005-06-22 2008-12-25 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法，およびその適応症
JP2009519917A (ja) * 2005-12-17 2009-05-21 パウル ハルトマン アクチェンゲゼルシャフト 有効成分を含む医薬組成物、及び組成物を含む創傷接触層
JP2012524058A (ja) * 2009-04-15 2012-10-11 フォンダツィオーネ アイアールシーシーエス イスティトゥト ナツィオナーレ デイ トゥモリ 血管透過性亢進の治療におけるマルチキナーゼ阻害剤の使用
JP2013523614A (ja) * 2010-03-26 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007832A (es) * 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
JP2007528393A (ja) * 2004-03-11 2007-10-11 カイセラ バイオファーマシューティカルズ， インコーポレイテッド 皮膚の状態および毛の状態を予防および処置するための組成物および方法
KR101713501B1 (ko) * 2008-03-17 2017-03-07 암비트 바이오사이언시즈 코포레이션 Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
CA2784807C (en) * 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2012006584A2 (en) * 2010-07-08 2012-01-12 Infinity Pharmaceuticals, Inc. Therapeutic regimens for hedgehog-associated cancers
WO2012051204A2 (en) * 2010-10-11 2012-04-19 Purdue Research Foundation Antimicrobial formulations that aid in wound healing
WO2012068468A1 (en) * 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
AU2012253525B2 (en) * 2011-05-10 2016-09-22 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
JP2015532272A (ja) * 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
CN103520162B (zh) * 2013-10-15 2015-11-18 中国科学院上海药物研究所 达拉菲尼抑制程序性坏死和保护肝脏的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506908A (ja) * 1996-12-20 2001-05-29 プロサイト コーポレイション 吸収性ヒドロゲル粒子および創傷用ドレッシングにおけるその使用
JP2003192598A (ja) * 2001-12-27 2003-07-09 Mikasa Seiyaku Co Ltd 創傷治療用製剤
JP2008546797A (ja) * 2005-06-22 2008-12-25 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法，およびその適応症
JP2009519917A (ja) * 2005-12-17 2009-05-21 パウル ハルトマン アクチェンゲゼルシャフト 有効成分を含む医薬組成物、及び組成物を含む創傷接触層
JP2012524058A (ja) * 2009-04-15 2012-10-11 フォンダツィオーネ アイアールシーシーエス イスティトゥト ナツィオナーレ デイ トゥモリ 血管透過性亢進の治療におけるマルチキナーゼ阻害剤の使用
JP2013523614A (ja) * 2010-03-26 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
高水 勝: "ドレッシング材を４つの視点で整理する", 薬局, vol. 第６４巻，第１２号, JPN6019008079, 2013, pages 2984 - 2994, ISSN: 0004159168 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530457A (ja) * 2017-08-08 2020-10-22 メモリアル スローン ケタリング キャンサー センター Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
JP2023021241A (ja) * 2017-08-08 2023-02-10 メモリアル スローン ケタリング キャンサー センター Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
JP7520093B2 (ja) 2017-08-08 2024-07-22 メモリアル スローン ケタリング キャンサー センター Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
JP2022519675A (ja) * 2019-02-12 2022-03-24 ルトリス ファーマ エル ティー ディー． 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用

Also Published As

Publication number Publication date
WO2015171833A1 (en) 2015-11-12
US20170100345A1 (en) 2017-04-13
EP3139927A4 (en) 2017-12-13
EP3139927A1 (en) 2017-03-15
CN106535900A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
JP2017514866A (ja) Ｂｒａｆ阻害剤を使用する創傷治癒
TWI812581B (zh) 激酶調節及其適應症
KR20180037228A (ko) 항박테리아 치료제 및 예방제
JP2020534285A (ja) 投与および処置の方法
JP2012520299A (ja) キナーゼタンパク質結合阻害剤
JP2018135342A (ja) 皮膚の病的状態を治療するための組成物及び方法
US20190262343A1 (en) Wound healing using braf inhibitors
CN105687185B (zh) 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法
WO2022159594A1 (en) Crystalline forms of a pyrrolopyridine-aniline compound
CN114615984A (zh) 作为klk5/7双重抑制剂的苯并噁嗪酮化合物
US20200306244A1 (en) Wnt inhibitors for use in the treatment of fibrosis
CN111867678B (zh) 治疗黑色素瘤的方法
TWI826738B (zh) 癌症治療方法
KR20200051690A (ko) 국소 조성물
CA2889010A1 (en) Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of cbp/catenin
US20240197666A1 (en) Diterpenoid compounds that act on protein kinase c (pkc)
KR20200051689A (ko) 국소 조성물 및 치료 방법
KR20080011280A (ko) 피부과학적 질병의 치료를 위한 피부과학적 조성물 및 염
EP3233189A1 (en) 3-(piperidin-4-yl)-isoxazol-3(2h)-ones for treatment of dermatologic disorders
JP2021500413A (ja) 一部の肉腫の治療に使用するためのｉｌ−８阻害薬
JP2025079327A (ja) Ｓｍａｄ非依存的ＴＧＦ－βシグナル伝達経路阻害剤、及びそれを含むがん浸潤及び／又は転移抑制組成物
CN118829432A (zh) 用于治疗癌症的ras抑制剂和法尼基转移酶抑制剂的组合
Caraglia et al. Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201110